Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.

MLA

Senecal, Frank M., et al. “Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 Microg Every 2 Weeks versus Epoetin Alfa 40,000 U Weekly.” Clinical Breast Cancer, vol. 6, no. 5, Dec. 2005, pp. 446–54. EBSCOhost, https://doi.org/10.3816/cbc.2005.n.050.

APA

Senecal, F. M., Yee, L., Gabrail, N., Charu, V., Tomita, D., Rossi, G., & Schwartzberg, L. (2005). Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clinical Breast Cancer, 6(5), 446–454. https://doi.org/10.3816/cbc.2005.n.050

Chicago

Senecal, Frank M, Lorrin Yee, Nashat Gabrail, Veena Charu, Dianne Tomita, Greg Rossi, and Lee Schwartzberg. 2005. “Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 Microg Every 2 Weeks versus Epoetin Alfa 40,000 U Weekly.” Clinical Breast Cancer 6 (5): 446–54. doi:10.3816/cbc.2005.n.050.